Drug Information

Drug General Information
Drug ID
D0P2QO
Former ID
DIB010332
Drug Name
S-15535
Synonyms
1-(1,4-Benzodioxan-5-yl)-4-(indan-2-yl)piperazine
Drug Type
Small molecular drug
Indication Anxiety disorder [ICD9: 300, 311; ICD10:F32, F40-F42] Phase 2 [539677], [545119]
Structure
Download
2D MOL

3D MOL
Formula
C21H24N2O2
InChI
InChI=1S/C21H24N2O2/c1-2-5-17-15-18(14-16(17)4-1)22-8-10-23(11-9-22)19-6-3-7-20-21(19)25-13-12-24-20/h1-7,18H,8-15H2
InChIKey
QJPPEMXOOWNICQ-UHFFFAOYSA-N
PubChem Compound ID
132787
PubChem Substance ID
10243194, 14900073, 26753615, 26753616, 29215165, 29310835, 48179689, 48253921, 57344259, 79460343, 85209810, 90340566, 103232002, 104378207, 121361753, 125820975, 134221970, 135087833, 135650960, 135651202, 136350534, 140448560, 144239784, 162223633, 162312694, 162793530, 163564828, 175612588, 179235771, 184538700, 204360580, 224956703, 227839306, 245590360, 252322750, 252815017
Target and Pathway
Target(s) 5-hydroxytryptamine 1A receptor Target Info Antagonist [525641], [551871]
KEGG Pathway cAMP signaling pathway
Neuroactive ligand-receptor interaction
Serotonergic synapse
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
5HT1 type receptor mediated signaling pathway
Reactome Serotonin receptors
G alpha (i) signalling events
WikiPathways Serotonin HTR1 Group and FOS Pathway
SIDS Susceptibility Pathways
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 539677(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 26).
Ref 545119Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002186)
Ref 525641S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br J Pharmacol. 1999 Nov;128(6):1207-14.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.